<P> The cost of treatment depends on the amount of growth hormone given, which in turn depends on the child's weight and age . One year's worth of drugs normally costs about US $20,000 for a small child and over $50,000 for a teenager . These drugs are normally taken for five or more years . </P> <P> From a social perspective shortness can be a problem independently of the cause . In many societies there are advantages associated with taller stature and disadvantages associated with shorter stature, and vice versa . </P> <P> Pharmaceutical companies Genentech and Eli Lilly, makers of human growth hormone, have worked to medicalize short stature by convincing the public that short stature is a disease rather than a natural variation in human height . Limiting sales of the hormone to children diagnosed with growth hormone deficiency, rather than being short for any reason, limited their sales market . Expanding it to all children whose height was below the third percentile would create 90,000 new customers and US $10 billion in revenue . In the early 1990s, they paid two US charities, the Human Growth Foundation and the MAGIC Foundation, to measure the height of thousands of American children in schools and public places, and to send letters urging medical consultations for children whose height was deemed low . Parents and schools were not told that the charities were being paid by the drug companies to do this . </P> <P> Paired with a campaign to advertise the hormone to physicians, the campaign was successful, and tens of thousands of children began receiving HGH . About half of them do not have growth hormone deficiency, and consequently benefited very little, if at all, from the hormone injections . Criticism of the universal screening program eventually resulted in its end . </P>

Hort stature due to hypopituitarism is called as